(将ARNI与ACEI进行前瞻性比较,以确定心力衰竭对全球死亡率和发病率的影响[范式-HF];NCT01035255) Footnotes ↵∗Drs. Myhre and Vaduganathan contributed equally to this work as co-first authors.The PARADIGM-HF trial was funded by ...
0.76-0.93). Death from CV causes occurred in 13.3% of patients assigned LCZ696 vs. 16.5% assigned enalapril (HR=0.8; 95% CI, 0.71-0.89). PARADIGM-HF was designed as a CV mortality trial, Packer said at a press conference.
ACEI/ARB+β受体阻滞剂+醛固酮拮抗剂已经成为临床射血分数降低心力衰竭(EFr HF)治疗的金标准.本文简述了PARADIGM-HF临床试验,结果显示:与依那普利组比较,LCZ696(ARNI)治疗组主要复合终点[HR 0.80(95%CI 0.73~0.87),P0.001],心血管死亡[HR 0.80(95%CI 0.71~0.89),P0.001],因心力衰竭住院[HR 0.79(95%CI 0.7...
the randomized, double-blind placebo-controlled EMPEROR--Preserved trial clearly showed the glucose-lowering sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin to reduce the combined risk of cardiovascular death, HF-related hospitalization, and emergency/urgent HF visits requiring intravenous t...
https:// doi.org/10.1056/nejmoa1501315 28. Günthard HF, Aberg JA, Eron JJ et al (2014) Antiretroviral treatment of adult HIV infection: 2014 Recommendations of the International Antiviral Society-USA panel. JAMA - J Am Med Assoc. 312(4):410–425. https:...